Vir Biotechnology (VIR) PT Raised to $61 at Goldman Sachs, Following Earnings
Tweet
Share
E-mailGet Alerts VIR Hot Sheet
Price: $46.38 +2.98%
Rating Summary:
6 Buy, 0 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 13 | New: 41
Rating Summary:
6 Buy, 0 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 13 | New: 41
Trade Now!
Join SI Premium – FREE
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Goldman Sachs analyst Paul Choi raised the price target on Vir Biotechnology (NASDAQ: VIR) to $61.00 (from $54.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GSK (GSK) and Vir Biotechnology (VIR) Announce EMA Review of Dual-Action Monoclonal Antibody VIR-7831 for the Early Treatment of COVID-19
- flatexDEGIRO AG (FTKn:GR) (FNNTF) PT Raised to EUR120 at Goldman Sachs
- Hana Financial Group (086790:KS) PT Raised to KRW51,000 at Morgan Stanley
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Goldman Sachs, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
